Hydrocortisone With or Without Mitoxantrone in Men With Hormone-Refractory Prostate Cancer: Results of the Cancer and Leukemia Group B 9182 Study
Philip W. Kantoff(Convergent Science (United States)), Nicholas J. Vogelzang(Comprehensive Cancer Centers of Nevada), Susan Halabi(Duke Medical Center), Eric P. Winer(University of Vermont), Mark R. Conaway(Duke Medical Center), Jeffrey Kirshner(Duke Medical Center), Vera Hárs, Donald L. Trump(Inova Health System), Joel Picus(Washington University in St. Louis)
Cited by 893
Related Papers
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
|New England Journal of Medicine|2010|5.5k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
|New England Journal of Medicine|2013|3.3k
Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma
|Journal of Clinical Oncology|2003|3.1k
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
|New England Journal of Medicine|2015|2.8k